First Western Trust Bank Has $990.26 Million Holdings in Stryker Co. (NYSE:SYK)

First Western Trust Bank boosted its position in shares of Stryker Co. (NYSE:SYK – Get Rating) by 0.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,050,298 shares of the medical technology company’s stock after buying an additional 1,387 shares during the quarter. Stryker makes up about 56.8% of First Western Trust Bank’s holdings, making the stock its biggest holding. First Western Trust Bank owned about 1.07% of Stryker worth $990,257,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Align Wealth Management LLC purchased a new position in Stryker during the 4th quarter valued at $25,000. MADDEN SECURITIES Corp purchased a new stake in shares of Stryker in the 4th quarter worth about $29,000. Elequin Securities LLC purchased a new stake in shares of Stryker in the 4th quarter worth about $29,000. Arcus Capital Partners LLC purchased a new stake in shares of Stryker in the 4th quarter worth about $30,000. Finally, Beirne Wealth Consulting Services LLC purchased a new stake in shares of Stryker in the 4th quarter worth about $30,000. 77.10% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Allan C. Golston sold 5,459 shares of the business’s stock in a transaction on Tuesday, February 28th. The shares were sold at an average price of $263.27, for a total value of $1,437,190.93. Following the sale, the director now owns 13,537 shares in the company, valued at $3,563,885.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Allan C. Golston sold 5,459 shares of the company’s stock in a transaction dated Tuesday, February 28th. The shares were sold at an average price of $263.27, for a total value of $1,437,190.93. Following the completion of the sale, the director now directly owns 13,537 shares of the company’s stock, valued at $3,563,885.99. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Srikant M. Datar sold 1,000 shares of the company’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $286.00, for a total transaction of $286,000.00. Following the completion of the sale, the director now directly owns 5,967 shares of the company’s stock, valued at $1,706,562. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of Stryker from $280.00 to $330.00 in a research report on Tuesday, May 2nd. Jefferies Financial Group upped their target price on shares of Stryker from $320.00 to $345.00 in a research report on Tuesday, May 2nd. Barclays increased their price objective on shares of Stryker from $314.00 to $321.00 in a research report on Tuesday, May 2nd. Royal Bank of Canada raised their price objective on shares of Stryker from $288.00 to $315.00 in a research note on Tuesday, May 2nd. Finally, 92 Resources restated a “maintains” rating on shares of Stryker in a research note on Tuesday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $302.00.

Stryker Price Performance

NYSE:SYK traded down $0.64 during trading hours on Friday, hitting $271.76. 394,380 shares of the stock traded hands, compared to its average volume of 1,302,437. The company has a quick ratio of 0.99, a current ratio of 1.73 and a debt-to-equity ratio of 0.70. Stryker Co. has a 1 year low of $188.84 and a 1 year high of $306.56. The company has a market cap of $102.95 billion, a price-to-earnings ratio of 39.65, a price-to-earnings-growth ratio of 2.85 and a beta of 0.94. The stock has a 50 day moving average price of $286.87 and a 200 day moving average price of $263.02.

Stryker (NYSE:SYK – Get Rating) last issued its quarterly earnings results on Monday, May 1st. The medical technology company reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.14. Stryker had a net margin of 13.86% and a return on equity of 22.17%. The business had revenue of $4.80 billion for the quarter, compared to the consensus estimate of $4.56 billion. During the same quarter in the previous year, the firm earned $1.97 earnings per share. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Sell-side analysts forecast that Stryker Co. will post 10.16 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.10%. The ex-dividend date of this dividend is Thursday, June 29th. Stryker’s payout ratio is currently 43.67%.

About Stryker

(Get Rating)

Stryker Corp. is a medical technology company, which engages in the provision of innovative products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery.